Shares of biotechnology company bioAffinity (NASDAQ:BIAF) are surging today after publishing peer-reviewed data on the analysis of sputum using high throughput flow cytometry.
BIAF’s noninvasive, early-stage diagnostics are targeted toward the detection of cancer and lung diseases.
The analysis uses flow cytometry as the basis to establish lung health. Importantly, the paper shows a method to study sputum to detect lung cancer and this can potentially be used in other diseases such as asthma and COPD.
Further, BIAF’s CyPath Lung test (its first offering) is currently marketed as an LDT or laboratory-developed test.
Read full Disclosure
